Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial

被引：0
|
作者：
Ismaila, Afisi S. [1 ,2 ]
Shah, Dhvani [3 ]
Martin, Alan [4 ]
Kendall, Robyn [5 ]
Noorduyn, Stephen G. [6 ]
Dasari, Priyadarsini [7 ]
Risebrough, Nancy A. [8 ]
Compton, Chris [9 ]
Noorduyn, Stephen G. [6 ]
机构：
[1] GSK, Value Evidence & Outcomes, Collegeville, PA USA
[2] McMaster Univ, Dept Hlth Res Methods, Evidence & Impact, Hamilton, ON, Canada
[3] ICON Plc, ICON Hlth Econ, Hillside, NJ USA
[4] GSK, Value Evidence & Outcomes, Brentford, Middx, England
[5] ICON Plc, ICON Hlth Econ, Vancouver, BC, Canada
[6] GSK Ontario, Value Evidence & Outcomes, Mississauga, ON, Canada
[7] ICON Plc, ICON Hlth Econ, Houston, TX USA
[8] ICON Plc, ICON Hlth Econ, Burlington, ON, Canada
[9] GSK, Value Evidence & Outcomes, R&D Global Med, Brentford, Middx, England
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
Treatments; COPD-management; Quality of life;
D O I：
10.1183/13993003.congress-2023.PA4698
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] BENEFIT-RISK PROFILES OF FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) VS UMEC/VI IN PATIENTS WITH COPD: A MARKOV MODEL
    Bratton, Daniel
    Hartley, Benjamin
    Barnes, Neil
    Brusselle, Guy
    Compton, Christopher
    Corbridge, Thomas
    Dransfield, Mark
    Halpin, David
    Han, Meilan
    Jones, Christine Elaine
    Jones, Paul
    Lange, Peter
    Lipson, David
    Martinez, Fernando
    Papi, Alberto
    Roche, Nicolas
    Singh, Dave
    Wise, Robert
    CHEST, 2020, 158 (04) : 1666A - 1671A
  • [2] Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation
    Mannino, David
    Bogart, Michael
    Germain, Guillaume
    Huang, Shirley P.
    Ismaila, Afisi S.
    Laliberte, Francois
    Jung, Young
    MacKnight, Sean D.
    Stiegler, Marjorie A.
    Duh, Mei Sheng
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2022, 17 : 491 - 504
  • [3] An Analysis of the IMPACT Trial Assessing Single-Inhaler Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI and UMEC/VI Using a Composite Adverse Event Outcome in Patients with COPD
    Wells, J. M.
    Bhatt, S. P.
    Carr, T. F.
    Criner, G. J.
    Halpin, D. M. G.
    Han, M. K.
    Jain, R.
    Kaye, M. G.
    Kraft, M.
    Lipson, D. A.
    Mapel, D.
    Mammen, M. J.
    McEvoy, C.
    Midwinter, D.
    Singh, D.
    Wise, R.
    Dransfield, M. T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [4] Characterization of Patients with Asthma Initiating Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)
    Wrobleski, Kristin
    Noorduyn, Stephen
    Lee, Lydia
    Igboekwe, Emmeline
    Liu, Meixia
    Veeranki, Phani
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB101 - AB101
  • [5] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Sandeep Bansal
    Martin Anderson
    Antonio Anzueto
    Nicola Brown
    Chris Compton
    Thomas C. Corbridge
    David Erb
    Catherine Harvey
    Morrys C. Kaisermann
    Mitchell Kaye
    David A. Lipson
    Neil Martin
    Chang-Qing Zhu
    Alberto Papi
    npj Primary Care Respiratory Medicine, 31
  • [6] Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
    Bansal, Sandeep
    Anderson, Martin
    Anzueto, Antonio
    Brown, Nicola
    Compton, Chris
    Corbridge, Thomas C.
    Erb, David
    Harvey, Catherine
    Kaisermann, Morrys C.
    Kaye, Mitchell
    Lipson, David A.
    Martin, Neil
    Zhu, Chang-Qing
    Papi, Alberto
    NPJ PRIMARY CARE RESPIRATORY MEDICINE, 2021, 31 (01)
  • [7] Efficacy of fluticasone furoate (FF)/vilanterol (VI) or FF alone in asthma patients with differing eosinophil (eos) levels
    Woodcock, Ashley
    Jacques, Loretta
    Leather, David
    Forth, Richard
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [8] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Afisi S. Ismaila
    Katrin Haeussler
    Alexandrosz Czira
    Ji-Hee Youn
    Mia Malmenäs
    Nancy A. Risebrough
    Jatin Agarwal
    Maria Nassim
    Raj Sharma
    Chris Compton
    Claus F. Vogelmeier
    MeiLan K. Han
    David M. G. Halpin
    Advances in Therapy, 2022, 39 : 3957 - 3978
  • [9] Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
    Ismaila, Afisi S.
    Haeussler, Katrin
    Czira, Alexandrosz
    Youn, Ji-Hee
    Malmenas, Mia
    Risebrough, Nancy A.
    Agarwal, Jatin
    Nassim, Maria
    Sharma, Raj
    Compton, Chris
    Vogelmeier, Claus F.
    Han, MeiLan K.
    Halpin, David M. G.
    ADVANCES IN THERAPY, 2022, 39 (09) : 3957 - 3978
  • [10] GENETIC VARIANTS DO NOT PREDICT ACUTE COPD EXACERBATIONS OR TREATMENT RESPONSE TO FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL (FF/UMEC/VI) AND ITS COMPONENTS
    Hosking, Louise
    Yeo, Astrid
    Hoffman, Joshua
    Chiano, Mathias
    Fraser, Dana
    Ghosh, Soumitra
    Lipson, David
    Martin, Neil
    Condreay, Lynn
    Cox, Charles
    Stjean, Pamela
    CHEST, 2020, 158 (04) : 1800A - 1801A
12345